Sepracor working with SmithKline on R-ketoprofen OTC analgesic project.
This article was originally published in The Tan Sheet
Executive Summary
SEPRACOR WORKING WITH SMITHKLINE ON R-KETOPROFEN OTC ANALGESIC PROJECT, Sepracor Chief Financial Officer David Southwell told securities analysts at the Dillon, Read generic drug and drug delivery conference in New York City May 11. SmithKline Beecham has recently taken over the project following its acquisition of the Sterling Winthrop OTC business outside the U.S. Sepracor and Sterling signed a co-development agreement on the single-isomer version of ketoprofen in December 1992, under which Sterling received worldwide OTC marketing rights.